In silico and experimental approaches for validating RNA editing events in transcriptomes

In silico and experimental approaches for validating RNA editing events in transcriptomes

As a typical RNA virus, SARS-CoV-2 is subjected to RNA editing in host cells. While some researchers believe that a traditional variant calling pipeline retrieves all true-positive RNA editing events from the transcriptome, others argue that conventional methods identify many false-positive sites. H...

Bibliografski detalji
Glavni autor:	Lai Wei
Format:	Članak
Jezik:	English
Izdano:	Taylor & Francis Group 2024-12-01
Serija:	RNA Biology
Teme:	RNA editing SARS-CoV-2 in silico experiment validation
Online pristup:	https://www.tandfonline.com/doi/10.1080/15476286.2024.2432729

Slični predmeti

Proof-of-concept for effective antiviral activity of an in silico designed decoy synthetic mRNA against SARS-CoV-2 in the Vero E6 cell-based infection model
od: Nofar Atari, i dr.
Izdano: (2023-04-01)

In silico screening of drug inhibitors of SARS-CoV-2 RNA-dependent RNA polymerase target
od: Thanh Tung Bui, i dr.
Izdano: (2022-03-01)

In silico study of the flavonoid compound of Sauropus androgynus leaves ON RNA-Dependent RNA polymerase (RdRp) SARS-CoV-2
od: Aghnia Nabila Ananda, i dr.
Izdano: (2024-06-01)

Ocular A-to-I RNA editing signatures associated with SARS-CoV-2 infection
od: Yun-Yun Jin, i dr.
Izdano: (2024-05-01)

Cnicin as an Anti-SARS-CoV-2: An Integrated In Silico and In Vitro Approach for the Rapid Identification of Potential COVID-19 Therapeutics
od: Hani A. Alhadrami, i dr.
Izdano: (2021-05-01)

RESIC: A Tool for Comprehensive Adenosine to Inosine RNA Editing Site Identification and Classification
od: Dean Light, i dr.
Izdano: (2021-07-01)

In silico analysis and identification of honey flavonoids as potential inhibitors of SARS-CoV-2 RNA-dependent RNA polymerase and main protease
od: Muhammad Abrar Yousaf
Izdano: (2022-06-01)

RNA editing in response to COVID-19 vaccines: unveiling dynamic epigenetic regulation of host immunity
od: Yun-Yun Jin, i dr.
Izdano: (2024-09-01)

Repurposing of Doxycycline to Hinder the Viral Replication of SARS-CoV-2: From in silico to in vitro Validation
od: Rajaiah Alexpandi, i dr.
Izdano: (2022-05-01)

Design of a multi-epitope vaccine using HA and M1 proteins from influenza and S, E, and M proteins from SARS-CoV-2 by in silico tools
od: Sharareh Jamali, i dr.
Izdano: (2023-01-01)

2-Phenoxyacetamide derivatives as SARS-CoV-2 main protease inhibitor: In silico studies
od: Pandu Hariyono, i dr.
Izdano: (2022-01-01)

Immunized mice naturally process in silico-derived peptides from the nucleocapsid of SARS-CoV-2
od: Mario Aldair Campos-Ruíz, i dr.
Izdano: (2023-10-01)

Analysis and Identification of Bioactive Compounds of Cannabinoids in Silico for Inhibition of SARS-CoV-2 and SARS-CoV
od: Chenxiao Chen, i dr.
Izdano: (2022-11-01)

Host-dependent C-to-U RNA editing in SARS-CoV-2 creates novel viral genes with optimized expressibility
od: Pirun Zhang, i dr.
Izdano: (2024-10-01)

In silico prediction of siRNA to silence the SARS-CoV-2 omicron variant targeting BA.4, BA.5, BQ.1, BQ1.1. and XBB: an alternative to traditional therapeutics
od: Rahatul Islam, i dr.
Izdano: (2023-08-01)

Immunogenic SARS-CoV-2 Epitopes: In Silico Study Towards Better Understanding of COVID-19 Disease—Paving the Way for Vaccine Development
od: Vipin Ranga, i dr.
Izdano: (2020-07-01)

In silico design of quadruplex aptamers against the spike protein of SARS-CoV-2
od: Mandana Behbahani, i dr.
Izdano: (2021-01-01)

Evaluation of Predicted siRNA as an Antiviral against MERS-CoV Targeting the Membrane Gene in the Vero Cell Line
od: Amany Y. El-Sayed, i dr.
Izdano: (2023-10-01)

Antiviral Activity of Metabolites from Peruvian Plants against SARS-CoV-2: An In Silico Approach
od: Luis Daniel Goyzueta-Mamani, i dr.
Izdano: (2021-06-01)

Nigella sativa L as a potential phytotherapy for coronavirus disease 2019: A mini review of in silico studies
od: Dr Abdulrahman E. Koshak, i dr.
Izdano: (2020-01-01)

Inhibitory potential of phytochemicals on five SARS-CoV-2 proteins: in silico evaluation of endemic plants of Bosnia and Herzegovina
od: Tarik Corbo, i dr.
Izdano: (2023-03-01)

Spike protein of SARS-CoV-2 Omicron variant: An in-silico study evaluating spike interactions and immune evasion
od: Jose A. Jimenez Ruiz, i dr.
Izdano: (2022-11-01)

An Immunoinformatics Approach for SARS-CoV-2 in Latam Populations and Multi-Epitope Vaccine Candidate Directed towards the World’s Population
od: Andrés Felipe Cuspoca, i dr.
Izdano: (2021-06-01)

Synthesis of New Organoselenium-Based Succinanilic and Maleanilic Derivatives and In Silico Studies as Possible SARS-CoV-2 Main Protease Inhibitors
od: Saad Shaaban, i dr.
Izdano: (2023-07-01)

Recommendations for detection, validation, and evaluation of RNA editing events in cardiovascular and neurological/neurodegenerative diseases
od: Korina Karagianni, i dr.
Izdano: (2024-03-01)

An in silico pipeline approach uncovers a potentially intricate network involving spike SARS-CoV-2 RNA, RNA vaccines, host RNA-binding proteins (RBPs), and host miRNAs at the cellular level
od: Massimiliano Chetta, i dr.
Izdano: (2022-09-01)

Feasibility of Known RNA Polymerase Inhibitors as Anti-SARS-CoV-2 Drugs
od: Ujjwal Neogi, i dr.
Izdano: (2020-04-01)

Strawberry and Ginger Silver Nanoparticles as Potential Inhibitors for SARS-CoV-2 Assisted by In Silico Modeling and Metabolic Profiling
od: Mohammad M. Al-Sanea, i dr.
Izdano: (2021-07-01)

Reduced A-to-I editing of endogenous Alu RNAs in lung after SARS-CoV-2 infection1
od: Philip S. Crooke, III, i dr.
Izdano: (2021-01-01)

Detailed Molecular Interactions of Favipiravir with SARS-CoV-2, SARS-CoV, MERS-CoV, and Influenza Virus Polymerases In Silico
od: Mitsuru Sada, i dr.
Izdano: (2020-10-01)

Unlocking the potential of in silico approach in designing antibodies against SARS-CoV-2
od: Tasshitra Subramaniam, i dr.
Izdano: (2025-02-01)

In Silico Screening and Testing of FDA-Approved Small Molecules to Block SARS-CoV-2 Entry to the Host Cell by Inhibiting Spike Protein Cleavage
od: E. Sila Ozdemir, i dr.
Izdano: (2022-05-01)

In Silico Design of Peptide-Based SARS-CoV-2 Fusion Inhibitors That Target WT and Mutant Versions of SARS-CoV-2 HR1 Domains
od: Shana V. Stoddard, i dr.
Izdano: (2021-07-01)

In Silico Screening of Drugs That Target Different Forms of E Protein for Potential Treatment of COVID-19
od: Gema Lizbeth Ramírez Salinas, i dr.
Izdano: (2023-02-01)

In silico study of intrinsic dynamics of full-length apo-ACE2 and RBD-ACE2 complex
od: Qing Liu, i dr.
Izdano: (2021-01-01)

Quantifying RNA Editing in Deep Transcriptome Datasets
od: Claudio Lo Giudice, i dr.
Izdano: (2020-03-01)

Validation of Rapid Antibody (IgM – IgG) Test Kit for SARS-CoV-2 Infection in Surabaya, Indonesia
od: Museyaroh Museyaroh, i dr.
Izdano: (2022-10-01)

Unraveling C-to-U RNA editing events from direct RNA sequencing
od: Adriano Fonzino, i dr.
Izdano: (2024-12-01)

In silico study of medicinal plants with cyclodextrin inclusion complex as the potential inhibitors against SARS-CoV-2 main protease (Mpro) and spike (S) receptor
od: Doni Dermawan, i dr.
Izdano: (2021-01-01)

In Silico Virtual Screening of Marine Aldehyde Derivatives from Seaweeds against SARS-CoV-2
od: Nalae Kang, i dr.
Izdano: (2022-06-01)